Abstract
CONTEXT: Carbon monoxide (CO) concentrations in exhaled air may impart a quick, non-invasive method to determine smoking status. Haras is a nutraceutical medication, which is slowly gaining recognition for its antioxidant and anti-inflammatory activities. AIMS: The effectiveness of the Haras therapy in smokers and non-smokers will be assessed by evaluating breath CO levels. METHODS AND MATERIALS: The study included 101 test subjects with 76 subjects of smokers and 25 subjects of non-smokers. Both the test groups were given 10 mL of Haras juice in divided doses per day for 30 days. The CO levels were evaluated using a breath analyser before drug trial and then on the 8(th), 15(th), 22(nd) and after the conclusion of the drug trial. STATISTICAL ANALYSIS USED: The Wilcoxon signed-rank test was used to compare the CO and carboxyhemoglobin levels among smokers and non-smokers. RESULTS: Smokers had higher mean percent carboxyhemoglobin and mean parts per million CO values than non-smokers, and the difference between the two was shown to be statistically significant (P < 0.001). It was also found to be statistically significant from the first day to the eighth day, the first day to the 15(th) day, the first day to the 20(th) second day, first day to the 30(th) day (P < 0.001). CONCLUSIONS: Haras can be used effectively as an alternative supportive treatment for the diminution of CO levels in smokers and non-smokers.